Nightstar Therapeutics Plc Quick Ratio (NITE) starting from the first quarter 2019 to first quarter 2017, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nightstar Therapeutics Plc  (NITE)

Nightstar Therapeutics Plc's Quick Ratio

NITE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Nightstar Therapeutics Plc's Cash & cash equivalent, this led to improvement in Nightstar Therapeutics Plc's Quick Ratio to 51.56, above Nightstar Therapeutics Plc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry Nightstar Therapeutics Plc booked the highest Quick Ratio than Nightstar Therapeutics Plc in the first quarter 2019. While Quick Ratio total ranking in the first quarter 2019 has deteriorated compared to the prior quarter from 81 to 85.

Explain Quick Ratio?
How much Cash & cash equivalents NITE´s has?
What are NITE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NITE Quick Ratio (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2		 (Dec 31 2017)
Q1
Y / Y Current Liabilities Change -30.61 % 70.21 % 93.68 % 50.75 % 167.23 %
Y / Y Cash & cash equivalent Change 18.59 % 26.87 % -64.45 % -67.86 % 1178.44 %
Quick Ratio MRQ 51.56 30.18 7.43 8.63 30.17
NITE's Total Ranking # 85 # 81 # 154 # 111 #
Seq. Current Liabilities Change -45.29 % -12.12 % 28.48 % 12.33 % 34.2 %
Seq. Cash & cash equivalent Change -6.52 % 256.9 % 10.61 % -67.86 % 0 %



Quick Ratio first quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 8
Overall Market # 85


Quick Ratio Statistics
High Average Low
54.41 40.47 22.78
(Dec 31 2018)   (Sep 30 2018)




Financial Statements
Nightstar Therapeutics Plc's Current Liabilities $ 3 Millions Visit NITE's Balance sheet
Nightstar Therapeutics Plc's Cash & cash equivalent $ 153 Millions Visit NITE's Balance sheet
Source of NITE's Sales Visit NITE's Sales by Geography


Cumulative Nightstar Therapeutics Plc's Quick Ratio

NITE's Quick Ratio for the trailling 12 Months

NITE Quick Ratio

 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months		 (Dec 31 2017)
12 Months
Y / Y Current Liabilities TTM Growth 39.97 % 85.27 % 131.25 % 222.83 % 764.61 %
Y / Y Cash & cash equivalent TTM Growth -21.72 % -4.31 % 28.8 % 208.04 % 5013.77 %
Quick Ratio TTM 20.86 18.38 18.73 27.73 37.3
Total Ranking TTM # 4240 # 4061 # 4130 # 3966 #
Seq. Current Liabilities TTM Growth -6.33 % 12.13 % 19.32 % 11.69 % 23.98 %
Seq. Cash & cash equivalent TTM Growth 6.31 % 10.04 % -19.41 % -16.97 % 29.95 %

Quick ratio ranking by company, industry and sector >> Back to NITE Financial Strength Comparisons >> Go to Compare NITE Quick Ratio to its Competitors

On the trailing twelve months basis NITE Cash & cash equivalent increased by 18.59 % in Q1 2019 year on year, while Current Liabilities dropped to $3 millions, this led to increase in in Nightstar Therapeutics Plc's Quick Ratio to 20.86, above NITE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 102 other companies have achieved higher Quick Ratio than Nightstar Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2018 from 4061 to 4240.

Explain Quick Ratio?
How much Cash & cash equivalents NITE´s has?
What are NITE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 103
Healthcare Sector # 838
Within the Market # 4240


trailing twelve months Quick Ratio Statistics
High Average Low
13.79 11.04 8.7
(Dec 31 2017)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2019, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2019 MRQ Cash & cash equivalentMar 31 2019 MRQ Current Liabilities
United Bancshares Inc  131.10 $ 18.538  Millions$ 0.141  Millions
Nightstar Therapeutics Plc  51.56 $ 153.457  Millions$ 2.976  Millions
Rubius Therapeutics Inc   49.36 $ 559.965  Millions$ 11.345  Millions
Kaleido Biosciences Inc   33.94 $ 121.340  Millions$ 3.575  Millions
Krystal Biotech Inc   32.89 $ 106.630  Millions$ 3.242  Millions
Dyadic International Inc   31.78 $ 39.754  Millions$ 1.251  Millions
Palisade Bio Inc   31.55 $ 4.005  Millions$ 0.127  Millions
Tcr2 Therapeutics Inc   30.18 $ 161.656  Millions$ 5.357  Millions
Orchard Therapeutics Plc  27.53 $ 295.407  Millions$ 10.730  Millions
Iovance Biotherapeutics inc   27.37 $ 440.018  Millions$ 16.078  Millions
Voyager Therapeutics Inc   25.23 $ 358.499  Millions$ 14.210  Millions
Scholar Rock Holding Corp  20.84 $ 159.666  Millions$ 7.660  Millions
Acceleron Pharma inc  18.81 $ 437.596  Millions$ 23.270  Millions
Adverum Biotechnologies Inc   17.86 $ 189.488  Millions$ 10.610  Millions
Allogene Therapeutics Inc   17.10 $ 466.140  Millions$ 27.265  Millions
Kodiak Sciences Inc   16.99 $ 81.075  Millions$ 4.773  Millions
Crispr Therapeutics Ag  15.41 $ 437.549  Millions$ 28.398  Millions
Quince Therapeutics Inc   14.72 $ 59.044  Millions$ 4.010  Millions
Ladrx Corporation  14.14 $ 20.052  Millions$ 1.418  Millions
Regenxbio Inc   13.33 $ 285.225  Millions$ 21.390  Millions
Tracon Pharmaceuticals Inc   12.73 $ 32.069  Millions$ 2.520  Millions
Curis Inc   11.44 $ 42.949  Millions$ 3.753  Millions
Vivosim Labs Inc   11.36 $ 36.477  Millions$ 3.212  Millions
Denali Therapeutics Inc   11.23 $ 485.481  Millions$ 43.244  Millions
Replimune Group Inc   11.09 $ 134.811  Millions$ 12.156  Millions
Tectonic Therapeutic Inc   10.92 $ 108.476  Millions$ 9.935  Millions
Surface Oncology Inc   10.91 $ 140.174  Millions$ 12.847  Millions
Applied Genetic Technologies Corporation  10.53 $ 89.235  Millions$ 8.474  Millions

Date modified: 2026-09-08T21:14:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.